A Plea to Improve Vaccination and Public Health Strategies Against COVID-19

The number of doses of vaccine against coronavirus disease (COVID-19) is limited in most countries but some doses are administrated to already immunized asymptomatic people. With serological triages, we could reach an effective collective immunization1 swifter and potentially reduce allergic/immunological reactions (anaphylaxis2), blood clots, or other uncommon disorders following vaccine(s). Triages should concern all people; anti-spike antibodies could be ignored after asymptomatic COVID-19 but could also be missing after symptomatic COVID-19 (T-cell immunity).3 For immunized people (post-infection or/and post-vaccination), persistent immunity could be assessed each 8 months4 or more, according to risk(s) of severe COVID-19 and death.5 Exceptions could be made, as a vaccine(s) could treat long COVID-19 cases in which anti-Spike antibodies seem insufficient but this hypothesis should be confirmed. Figure 1 illustrates the suggested guidelines for vaccination.